A Population Based Study on Hepatitis B Virus in Northern Iran, Amol

Hossein Keyvani 1; Masoudreza Sohrabi 2; Farhad Zamani 2; Hossein Poustchi 3; Hossein Ashrafi 4; Fatemeh Saeedian 2; Mansooreh Mooadi 2; Nima Motamed 2; Hossein Ajdarkosh 2; Mahmoodreza Khonsari 5; Gholamreza Hemmasi 6; Mitra Ameli 2; Ali Kabir 5; Mahmoud Khodadost 2

1 Department of Virology, Iran University of Medical Sciences, Tehran, IR Iran
2 Gastrointestinal and Liver Diseases Research Center (GILDRC), Iran University of Medical Sciences, Tehran, IR Iran
3 Liver and Pancreatobiliary Disease Research Center, Digestive Disease Research institute (DDRI), Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Pathology, Kingston University, London, UK
5 Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

*Corresponding Author: Farhad Zamani, Gastrointestinal and Liver Disease Research Center (GILDRC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, IR Iran. Tel: +98-2188940489, Fax: +98-2188940489, E-mail: zamani.farhad@gmail.com

1. Background

Viral hepatitis is a major health problem worldwide. Change in transmission patterns of hepatitis B makes it necessary to re-evaluate its prevalence and risk factors.

Objectives: We aimed to determine the prevalence of HBV infection and its related risk factors in Amol city, Northern Iran.

Patients and Methods: As a population based study, a cluster sampling approach was used and 6446 individuals from the general population of urban and rural areas of Amol, Iran, from both genders and different ages were enrolled. Inclusion criteria were willingness to participate in the study, being a lifelong resident in Amol city or its surrounding areas with Iranian nationality. Ten milliliters (10 mL) of blood was taken from each study subject and checked regarding hepatitis B markers including HbsAg, HbsAb and HbcAb using a third generation ELISA. The prevalence of HBV infections and its potential risk factors were recorded.

Results: The prevalence of HbsAg, HbsAb and HbcAb were estimated as 0.9%, 30.7% and 10.5%, respectively. The mean age of all participants was 43.9 (95% CI: 43.4, 44.3) in females and 55.6 in (n = 3472) males. In our study, there was a significant association between family history of hepatitis, rural residency and presence of HbsAg. There was also a positive correlation between HbcAb and family history of hepatitis, history of other types of hepatic diseases, history of tattooing, traditional phlebotomy, male gender and age. In backward logistic regression, a significant association was found between history of hepatitis in first-degree family members (OR = 13.35; 95% CI: 6.26, 28.47) and place of residence (OR = 2.32; 95% CI: 1.27, 4.22) with presence of HbsAg. There was also a positive correlation between history of hepatitis among first-degree family members (OR = 2.49; 95% CI: 1.52, 4.08), history of tattooing (OR = 2.13; 95% CI: 1.33, 3.42), history of previous hepatitis (OR = 1.87; 95% CI: 1.06, 3.28), male sex (OR = 1.36; 95% CI: 1.12, 1.66) and age (OR = 1.03; 95% CI: 1.01, 1.04) with presence of HbcAb.

Conclusions: The prevalence of hepatitis B in Amol City and its surrounding areas was about one percent, a lower rate than other reports from Iran.

Keywords: Hepatitis B Virus; Infection; HbsAg; Prevalence; Epidemiology

1. Background

It is estimated that more than 400 million individuals have hepatitis B (HBV) infection worldwide. This infection is one of the top ten leading causes of death overall (1-3). In this context, understanding regional and demographic specific prevalence of hepatitis B infection is an important issue for evaluation, national prevention programs and control of disease. A matter of greater importance is assessment of the prevalence of HBV infection regarding its transmission and demographic variation in each territory. However, global seroprevalence statistics of HBV cannot explain each region current situation, moreover vaccination and other preventive policies around the world probably making change the epidemiological schema of HBV around the world.

The prevalence of hepatitis B varies among different countries ranging from 0.1% in Western countries to 35% in Southeast of Asia (3-5). The prevalence of hepatitis B infection in the Middle East varies among its geographic areas. While Kuwait and Bahrain have a low prevalence of hepatitis B infection of about 2%, countries like Iraq and United Arab Emirates have a prevalence of 2-5% (6, 7).

The prevalence of HBV infection in Iran varies within its geography (8). Recent data showed the overall prevalence of HBV in Iran as less than 3% (8, 9). Despite the fact, the prevalence of hepatitis B surface antigen in Iran has declined significantly during the last two decades from 3.4-8% in 1979 to 1-3% in 2000 (8, 9). So far, chronic hepatitis B remains the cause of more than 50% of cirrhosis and HCC in Iran (8, 10, 11). According to a systemic review in 2008, the seroprevalence of HBV in Iran was reported as 2.14%, although it did not reflect all provinces of Iran (12).

In addition, a nationwide study performed by the Iranian...
Blood Transfusion Organization demonstrated that the rate of HBV infection among volunteer blood donors had decreased from 1.8% to 0.4% between 1998 and 2007 (13). A rise in general public awareness about HBV transmission along with the mass vaccination program from 1993 for all neonates and healthcare workers and those at risk of HBV infection have influenced the outcome (11,14). Despite these studies, there is not enough data information about the epidemiology of HBV infection in various parts of Iran. Furthermore, it seems that risk factors vary among different regions within the country; thus, determination of risk factors and establishment of the main routes of HBV transmission could in turn help health administrations design effective prevention policies. Prevalent routes of HBV transmission include prenatal infection, sexual contact, intravenous narcotic use and transfusion. The most common route of transmission of hepatitis B in Iran was vertical transmission in the past, but other routes of transmission should also be considered. Although global vaccination program against hepatitis B decreased the rate of hepatitis B carriers, the rate of hepatitis B infected subjects remains noticeably high. This may reflect changes in patterns of epidemiology and transmission of HBV, producing some problems for healthcare systems (14-17).

2. Objectives
In this study, we tried to determine the prevalence and common risk factors of HBV infection in Amol city, Mazandaran province, Northern Iran.

3. Patients and Methods
3.1. Study Area and Population
Mazandaran province is located in North of Iran and Amol is a large city within this area with a population of more than 300,000. There is an almost equal distribution regarding the number of its rural and urban inhabitants, providing adequate sample size for comparison between these inhabitants. Furthermore, due to a low rate of migration to and from this area, the ethnicity of the residents has to a large extent remained unchanged largely. The study was performed as a part of a health cohort conducted in Amol from 2008 to 2011, by the Gastrointestinal and Liver Disease Research Centre (GILDRC) on the above population to determine the prevalence of HBV infection and its risk factors. Those enrolled were older than 10 years. Urban areas were considered as urbanized municipal areas and rural areas were those with agricultural areas. Inclusion criteria were Iranian nationality, lifelong residency in Amol or its vicinity, and willingness to participate in the study.

3.2. Sample of Study
A clustered random sampling was used, and Health Centers (HC) were considered as clusters. Each health center provided services to an average of 30 households. In this study, 24 and 16 urban and rural health centers were selected, respectively. From each health center, households were selected randomly. Then from each family, one male and one female member were chosen randomly. Finally, the total population was 6446 subjects.

3.3. Data Collection and Laboratory Tests
The researchers held face-to-face interviews with participants in health centers, between 2008 and 2011. When participants failed to attend their three scheduled interviews, an appointment was offered at their homes. When a subject refused to participate in this study, they were replaced other participants from their same cluster. Subjects were asked to complete a questionnaire containing information about age (number of years according to their Identification documents), gender (male or female), marital status (single or married based on the subject’s own responses), family history (first degree relative: father, mother, wife/husband, siblings; second degree relatives: uncles, aunts; third degree relatives: extended family), occupation (high-risk jobs such as medical staff and nursing home workers), literacy level (five level: illiterate, < 6 years of schooling, ≤ 12 years of schooling, ≤ bachelor’s degree holder, ≥ master’s degree holder), blood transfusion history, history of surgery (both minor and major operation), viral hepatitis (hepatitis C, hepatitis B), narcotic drug use (usual use of narcotics or drugs more than once weekly), smoking (active smoker or passive), tattooing and piercing (presence of figures, or sign or scars), cupping and blood-letting (yes or no; based on the response of subjects to question). All those eligible to participate were referred to the Amol Research Station (ARS) in the Haraz Clinic, affiliated to the GILDRC, for completion of clinical and laboratory evaluations. HBV markers including HbsAg, HBsAb and HBCAb were evaluated using a third generation ELISA (Enzyme-Linked Immuno-Sorbent Assay) method by Acon kits (Acon lab. San Diego. CA92121, USA).

3.4. Statistical Analysis
Data was analyzed using STATA software, version 12 (StataCorp, Texas, USA). Since data were considered as aggregated and our sampling was conducted, we used survey data analysis methods for all computations. Each health center was considered a cluster and each participant was designated to a certain cluster. Health centers defined as ‘strata’ and the population represented by each strata used for ‘finite population correction’ using STATA ‘survey data analysis’. The data was weighted by the proportion of the population represented by each strata (health centers) to the selected subjects number of each health centers. We used survey data analysis methods to estimate more accurate HBV infection
prevalence and risk factors including weighted point estimates prevalence rates of HBV biomarkers and their estimated 95% confidence intervals. ‘Proportions for survey data’ were used to calculate proportions and 95% confidence intervals. ‘Means estimate for survey data’ were used to calculate means and 95% confidence intervals. A ‘two-way table for survey data’ was used to investigate the association between HBV biomarkers and other variables. All confidence intervals, chi-square and P-values reported here were corrected for the cluster survey design using STATA ‘survey data analyses. ‘Logistic regression for survey data (backward method)’ was used to identify predictors of high-risk hepatitis B infection. All variables with p-values less than 0.20 were included in this model. A P value less than 0.05 was considered significant.

3.5. Ethics

Participants were informed about the project and written consent was obtained from all of them before data collection. All data was securely recorded in the study database. The study protocol and consent form were approved by the Board of Ethics of the GILDRC.

4. Results

4.1. Statistical Characteristics of Subjects

From 7000 subjects who were invited, 6146 cases (response rate = 87.8%) accepted to participate. Sixty-four subjects were excluded because of uncompleted data. Of 6146 subjects 3472 (55.6%) were male. The mean age of participants was 43.9 (95% CI: 43.4, 44.3) and 3006 (38.7%) were from rural areas. The mean age of rural participants was 43.54 (95% CI: 42.7, 44.06) and 63% (n = 1893) were male. For urban cases, these values were 44.2 (95% CI: 43.5, 44.8) and 50.9% (n = 1579), respectively. Of all participants, 286 (4.6%) individuals were younger than 18 years.

4.2. Prevalence of HBV Markers

Using survey data analysis method, the prevalence of HBsAg, HBsAb and HBcAb were estimated as 0.9% (95% CI: 0.6, 1.2%), 30.7% (95% CI: 29.3, 32%) and 10.5% (95% CI: 9.6, 11.4%), respectively. In total, 286 individuals were younger than 18 years, of whom 98 (37.8%) had HBsAb levels more than ten microliters. Moreover, 459 (8.27%) individuals had positive results for both HBsAb and HBcAb (Resolved infection) and 1231 (22.43%) individuals were HBsAb positive but HBcAb negative (Table 1).

4.3. Prevalence of HBV Risk Factors

Distribution of potential HBV risk factors between positive HBsAg and HBcAb subjects were shown in Table 2. Family history of hepatitis, rural residency and history of surgery were significantly associated with presence of HBsAg. Furthermore, there was a significant association between family history of hepatitis, family history of cirrhosis, male gender, history of traditional phlebotomy and history of tattooing with the presence of HBcAb.

4.4. Association Between HBV Markers and its Risk Factors

Logistic regression analysis was used to calculate the odds ratios for main risk factors (Tables 3 and 4). In univariate logistic regression (model 1), there was a significant association between history of hepatitis in family members (OR = 12.77), rural region residents (OR = 2.15), and the presence of HBsAg. There was also a positive correlation between HBcAb and history of hepatitis in family members (OR = 2.7), history of other types of hepatic diseases (OR = 1.9), history of tattooing (OR = 1.7), traditional phlebotomy (OR = 1.5), male sex (OR = 1.3) and age (OR = 1.03).

| HBV Markers | Total | Urban | Rural |
|-------------|-------|-------|-------|
|             | Male  | Female| Male  | Female|
| HBsAg+ b    | 62 (0.92) | 16 (0.92) | 6 (0.34) | 27 (1.39) | 13 (1.32) |
| HBsAb+ c    | 1693 (30.73) | 438 (31.79) | 456 (35.12) | 513 (27.26) | 286 (25.99) |
| HBcAb+ d    | 639 (10.56) | 190 (12.38) | 128 (8.57) | 213 (11.15) | 108 (9.79) |
| HBsAb+ and HBcAb+ | 459 (8.27) | 127 (9.7) | 93 (6.99) | 156 (8.24) | 83 (7.98) |
| HBsAb+ and HBcAb- | 1231 (22.43) | 311 (22.11) | 363 (28.12) | 356 (18.99) | 201 (17.85) |
| HBsAb- and HBcAb+ | 144 (2.26) | 39 (2.61) | 24 (1.62) | 57 (2.9) | 24 (1.72) |

Data are presented as No. (%).

a Hepatitis B surface antigen.
b Hepatitis B surface antibody.
c Hepatitis B core antibody.
d Hepatitis B core antibody.
Table 2. Distribution of HBV Risk Factors Regarding HBV Markers

| Variables                      | HBsAg | HBcAb |
|--------------------------------|-------|-------|
|                                | Total | Positive | P Value | Total | Positive | P Value |
| Gender                         |       |          |         |       |          |         |
| Male                           | 3469  | 43 (1.13) | 0.09    | 3469  | 403 (11.84) | 0.001   |
| Female                         | 2608  | 19 (0.65)  | 2606  | 236 (8.96)   |         |
| Total                          | 6077  | 62 (1.02)  | 6075  | 639 (10.51)  |         |
| Region                         |       |          |         |       |          |         |
| Rural                          | 3006  | 40 (1.36)  | 3003  | 312 (10.64)  | 0.87    |
| Urban                          | 3071  | 22 (0.63)  | 3072  | 318 (10.51)  |         |
| Total                          | 6077  | 62 (1.02)  | 6075  | 639 (10.51)  |         |
| History of surgery             |       |          |         |       |          |         |
| Yes                            | 2687  | 20 (0.63)  | 2684  | 315 (10.14)  | 0.44    |
| No                             | 3266  | 41 (1.24)  | 3257  | 324 (10.11)  |         |
| Total                          | 6013  | 61 (1.01)  | 6011  | 625 (10.39)  |         |
| History of unsterile puncture  |       |          |         |       |          |         |
| Yes                            | 1290  | 10 (0.75)  | 1288  | 135 (10.14)  | 0.71    |
| No                             | 4730  | 51 (1.07)  | 4729  | 493 (10.52)  |         |
| Total                          | 6020  | 61 (1.01)  | 6018  | 574 (9.53)   |         |
| History of blood transfusion   |       |          |         |       |          | 0.06    |
| Yes                            | 350   | 6 (1.88)   | 350   | 51 (10.68)   |         |
| No                             | 572   | 55 (0.95)  | 572   | 577 (10.24)  |         |
| Total                          | 602   | 61 (1.01)  | 602   | 628 (10.43)  |         |
| History of traditional phlebotomy | 602   | 61 (1.01)  | 602   | 628 (10.43)  | 0.002   |
| Yes                            | 460   | 6 (1.35)   | 460   | 70 (15.11)   |         |
| No                             | 5561  | 55 (0.98)  | 5561  | 558 (10.05)  |         |
| Total                          | 6021  | 61 (1.01)  | 6021  | 628 (10.43)  |         |
| Family history of hepatitis    |       |          |         |       |          | < 0.001 |
| First degree                   | 145   | 14 (0.96)  | < 0.001 | 145   | 37 (25.35)  |         |
| Second degree                  | 75    | 1 (0.13)   | 74    | 14 (15.69)   |         |
| Third Degree                   | 53    | 0          | 53    | 8 (14.83)    |         |
| No                             | 5750  | 46 (0.80)  | 5749  | 569 (9.95)   |         |
| Total                          | 6022  | 61 (1.01)  | 6022  | 628 (10.43)  |         |
| History of Tattooing           |       |          |         |       |          | 0.01    |
| Yes                            | 194   | 4 (1.65)   | 194   | 26 (16.92)   |         |
| No                             | 5828  | 57 (0.98)  | 5828  | 602 (10.24)  |         |
| Total                          | 6022  | 61 (1.01)  | 6020  | 628 (10.43)  |         |
| History of imprisonment        |       |          |         |       |          | 0.76    |
| Yes                            | 86    | 1 (0.12)   | 86    | 9 (10.47)    |         |
| No                             | 5933  | 60 (0.99)  | 5931  | 619 (10.47)  |         |
| Total                          | 6019  | 61 (1.01)  | 6017  | 628 (10.43)  |         |
| High risk occupational         |       |          |         |       |          | 0.25    |
| Yes                            | 58    | 0          | 58    | 8 (15.65)    |         |
| No                             | 5958  | 61 (0.98)  | 5956  | 620 (10.40)  |         |
| Total                          | 6016  | 61 (1.01)  | 6014  | 628 (10.43)  |         |
| History of unsafe sexual contact|     |          |         |       |          | 0.43    |
| Yes                            | 26    | 0          | 26    | 1 (6.20)     |         |
| No                             | 5992  | 61 (0.96)  | 5990  | 626 (10.47)  |         |
| Total                          | 6018  | 61 (1.01)  | 6016  | 628 (10.43)  |         |
| History of IDU                |       |          |         |       |          | 0.10    |
| Yes                            | 27    | 0          | 27    | 0          |         |
| No                             | 5994  | 61 (0.99)  | 5992  | 627 (10.48)  |         |
| Total                          | 6021  | 61 (1.01)  | 6019  | 627 (10.41)  |         |

| Note                  |   |
|-----------------------|--|
| a Data are presented as No. (%)   |   |
| b Hepatitis B surface antigen | |   |
| c Hepatitis B core antibody | |   |
| d P-value for HBV risk factors regarding HBsAg. | |   |
| e P-value for HBV risk factors regarding HBcAb. | |   |
| f Intravenous drug user. | |   |
### Table 3. Logistic Regression for Assessing Association Between HbsAg and Related Risk Factors

| Variables                                      | OR (95% CI) Model 1 | OR (95% CI) Model 2 | OR (95% CI) Model 3 | OR (95% CI) Model 4 |
|------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| **Gender**                                     |                     |                     |                     |                     |
| Male                                           | 1.72 (0.90 - 3.27)  | 1.72 (0.90 - 3.27)  | 1.33 (0.52 - 3.35)  | -                   |
| Female                                         | Reference           | Reference           | Reference           | -                   |
| Age, y                                         | 1.00 (0.99 - 1.02)  | 1.00 (0.99 - 1.02)  | -                   | -                   |
| **Region**                                     |                     |                     |                     |                     |
| Rural                                          | 2.15 (1.18 - 3.92)  | 2.05 (1.10 - 3.83)  | 2.32 (1.23 - 4.37)  | 2.32 (1.27 - 4.22)  |
| Urban                                          | Reference           | Reference           | Reference           | Reference           |
| **Family history of hepatitis**                |                     |                     |                     |                     |
| First degree                                    | 12.77 (6.27 - 27.19)| 13.68 (6.36 - 29.44)| 12.60 (5.88 - 27.03)| 13.35 (6.26 - 28.47)|
| Second degree                                   | 1.79 (0.24 - 13.09) | 1.88 (0.25 - 13.73) | 1.54 (0.23 - 9.98)  | 1.73 (0.23 - 12.56) |
| Third degree                                    | 0.29 (0.04 - 1.91)  | 0.35 (0.05 - 2.26)  | 0.38 (0.05 - 2.47)  | 0.33 (0.05 - 2.11)  |
| No                                             | Reference           | Reference           | Reference           | Reference           |
| **History of blood transfusion**               | 2.22 (0.78 - 6.34)  | 2.21 (0.74 - 6.61)  | 2.35 (0.81 - 6.76)  | -                   |
| **History of surgery**                         | 0.55 (0.30 - 0.99)  | 0.56 (0.31 - 1.03)  | 0.55 (0.28 - 1.09)  | -                   |
| **History of imprisonment**                    | 1.20 (0.16 - 8.73)  | 0.92 (0.12 - 6.78)  | -                   | -                   |
| **History of IDU**                             | 1.74 (0.10 - 28.37) | -                   | -                   | -                   |
| **History of tattooing**                       | 1.87 (0.60 - 5.78)  | 1.89 (0.61 - 5.83)  | 1.87 (0.65 - 5.37)  | -                   |
| **History of traditional phlebotomy**          | 1.29 (0.54 - 3.12)  | 1.18 (0.46 - 2.99)  | -                   | -                   |
| **History of unsterile puncture**              | 0.56 (0.27 - 1.18)  | 0.78 (0.29 - 2.08)  | 0.70 (0.25 - 1.90)  | -                   |
| **High risk occupation**                       | 0.89 (0.05 - 14.32)| -                   | -                   | -                   |
| **History of Alcohol addiction**               | 1.36 (0.41 - 4.53)  | 1.12 (0.33 - 3.83)  | -                   | -                   |
| **History of other types of hepatitis**        | 1.99 (0.75 - 5.18)  | 1.97 (0.74 - 5.23)  | 1.63 (0.39 - 6.78)  | -                   |
| **History of unsafe sexual contact**           | 1.80 (0.11 - 29.46)| -                   | -                   | -                   |

*a Crude Odds Ratio.
*b Adjusted Odds Ratio for sex and age.
*c Adjusted Odds Ratio (all variables with p-value < 0.2 entered the model such as sex, region, family history of hepatitis and history of blood transfusion, surgery, tattooing, unsterile puncture, icterus and other types of hepatitis).
*d Multivariable backward logistic regression model.
*e Intravenous drug user.

### Table 4. Logistic Regression for Assessing Association Between HBcAb and Related Risk Factors

| Variables                                      | Model 1, OR (95% CI) | Model 2, OR (95% CI) | Model 3, OR (95% CI) | Model 4, OR (95% CI) |
|------------------------------------------------|----------------------|----------------------|----------------------|----------------------|
| **Gender**                                     |                      |                      |                      |                      |
| Male                                           | 1.36 (1.12 - 1.64)   | 1.03 (1.01 - 1.04)   | 1.37 (1.12 - 1.67)   | 1.36 (1.12 - 1.66)   |
| Female                                         | Reference            | Reference            | Reference            | Reference            |
| Age, y                                         | 1.03 (1.01 - 1.04)   | 1.34 (1.11 - 1.63)   | 1.03 (1.01 - 1.04)   | 1.03 (1.01 - 1.04)   |
| **Region**                                     |                      |                      |                      |                      |
| Rural                                          | 1.01 (0.84 - 1.21)   | 0.99 (0.82 - 1.20)   | -                    | -                    |
| Urban                                          | Reference            | Reference            | -                    | -                    |
| **Family history of hepatitis**                |                      |                      |                      |                      |
| First degree                                    | 2.78 (1.81 - 4.26)   | 2.13 (1.98 - 4.97)   | 2.40 (1.45 - 3.97)   | 2.49 (1.52 - 4.08)   |
| Second degree                                   | 1.68 (0.88 - 3.21)   | 1.77 (0.91 - 3.42)   | 1.31 (0.69 - 2.46)   | 1.39 (0.74 - 2.61)   |
| Third degree                                    | 2.23 (0.94 - 5.29)   | 2.76 (1.06 - 7.13)   | 2.50 (0.97 - 6.43)   | 2.50 (0.97 - 6.43)   |
| No                                             | Reference            | Reference            | Reference            | Reference            |
| **History of blood transfusion**               | 1.18 (0.97 - 1.97)   | 1.17 (0.81 - 1.70)   | -                    | -                    |
| **History of surgery**                         | 1.07 (0.89 - 1.29)   | 0.92 (0.76 - 1.12)   | -                    | -                    |
| **History of imprisonment**                    | 0.89 (0.43 - 1.82)   | 0.64 (0.31 - 1.34)   | -                    | -                    |
| **History of IDU**                             | 1.42 (0.009 - 2.51)  | -                    | -                    | -                    |
| **History of tattooing**                       | 1.78 (1.13 - 2.84)   | 2.19 (1.36 - 3.52)   | 2.14 (1.33 - 3.43)   | 2.13 (1.33 - 3.42)   |
| **History of traditional Phlebotomy**          | 1.59 (1.17 - 2.15)   | 1.10 (0.81 - 1.50)   | 1.06 (0.77 - 1.54)   | -                    |
| **History of unsterile puncture**              | 0.95 (0.76 - 1.19)   | 1.05 (0.79 - 1.40)   | -                    | -                    |
| **High risk occupation**                       | 1.59 (0.70 - 3.59)   | 1.79 (0.79 - 4.07)   | -                    | -                    |
| **History of Alcohol addiction**               | 1.12 (0.67 - 1.88)   | 1.21 (0.71 - 2.05)   | -                    | -                    |
| **History of other types of hepatitis**        | 1.99 (1.07 - 3.72)   | 1.95 (1.14 - 3.33)   | 1.84 (1.04 - 3.25)   | 1.87 (1.06 - 3.28)   |
| **History of unsafe sexual contact**           | 0.56 (0.13 - 2.40)   | 0.65 (0.35 - 2.88)   | -                    | -                    |

*a Crude Odds Ratio.
*b Adjusted Odds Ratio for sex and age.
*c Adjusted Odds Ratio (all variables with p-value < 0.2 entered the model such as sex, age, family history of hepatitis, family history of cirrhosis and history of tattooing, traditional phlebotomy, icterus and other types of hepatitis).
*d Multivariable backward logistic regression model.
*e Intravenous drug user.
In multivariable logistic regression, after adjustment for demographic variables such as age and sex (Model 2), there was a significant association between family history of hepatitis (OR = 13.6), and rural residency (OR = 2) with the presence of HBsAg. There was also a positive correlation between HBcAb and history of tattooing (OR = 2.1), family history of hepatitis B (OR = 2.1) and history of other types of hepatic diseases (OR = 1.95) in a similar model adjusted for age and sex.

In model 3, all variables with p-values less than 0.2 included in the model. There was a significant association between history of hepatitis in family members (OR = 12.6) and rural region (OR = 2.3) with the presence of HBsAg. Finally, in the backward method of multivariable logistic regression (model 4), we found a significant association between history of hepatitis in first relative members (OR = 13.3) and region (OR = 2.3) with the presence of HBsAg. A history of hepatitis in first-degree relatives (OR = 2.4), history of tattooing (OR = 2.1), history of other types of hepatitis disease (OR = 1.8), male sex (OR = 1.3) and age (OR = 1.03) with the presence of HBcAb in this model (Tables 3 and 4).

5. Discussion

In this survey, serum samples of 6082 subjects were evaluated for the presence of HBsAg and HBcAb. According to our survey analyses, the prevalence of HBsAg and HBcAb were 0.9% and 10.5%, respectively.

In our study, the prevalence of HBsAg as an indicator of chronic hepatitis B infection was lower than other parts of Iran and lower than the national prevalence rate. Zali et al. and Alavian et al. revealed a prevalence of 1.7% and 2.14% for HBsAg in the general population of Iran (8, 12), indicating that the rate of HBV infection does not follow a consistent pattern in various geographical areas within the country. Table 5 summarizes some population based studies published on the prevalence of HBsAg in Iran. According to these studies, the highest prevalence of HBV infection was in Golestan province (18) northeast of Iran and the lowest rate of HBV infection in Azarbayjan province (12) northwest of Iran. Although, the frequency of hepatitis B was significantly different in Amol located between these two areas and adjacent to Golestan province (0.9% vs. 5.1%). We could not express a clear explanation about these differences, but it might be due to lifestyle, population density, interfamilial contact, public education about HBV infection and successful anti HBV vaccination. Nationwide vaccination against HBV was introduced in Iran since 1992; therefore, subjects younger than 18 years had received vaccination against HBV. In this population, lower expected number of subjects with positive HBsAb (37.8%) might be due to the decreasing level of antiHBs during the time after vaccination.

HBcAb is another marker of viral hepatitis B and an indicator of past exposure to HBV. Positive results for HBcAb could be considered as a potential threat for transmission of hepatitis B infection (19, 20). Moreover, a noticeable proportion of population with positive HBcAb has occult HBV infection with undetectable HBV-DNA and negative results for serum HBsAg. In this situation, further follow-up and careful evaluation of patients is needed. However, the prevalence of this HBV marker is not similar in different geographic areas of Iran. As illustrated in Table 5, our results showed a lower prevalence of HBcAb compared to other parts of Iran (12, 18, 19, 21-24). It seems that cultural factors and lack of accurate implementation of health guidelines might affect the distribution of HBV infection. The differences between prevalence of hepatitis B markers in different parts of Iran may be related to some traditional lifestyle factors, population density, public knowledge and education about HBV transmission. Mass vaccination program and active follow-up of patients with HBV infection by health service providers had a significant influence on the rate of infection. However, it is not an easy task to compare different prevalence rates among provinces of Iran.

Multivariate analysis showed that HBsAg positivity was significantly correlated with family history of hepatitis and rural residency as independent risk factors. Our results revealed that all age groups and particularly males had exposure to HBV. Furthermore, family history, tattooing, male gender, age of hepatitis and tattooing had significant correlations with the presence of HBcAb (Tables 3 and 4).

In almost all previous studies in Iran, age was considered a predictive risk factor in accordance with our study (Figure 1) (17, 18, 23, 25). This fact could be attributed to the mass national vaccination program in Iran from 1992 covering the young population; therefore, older populations had not received vaccination against HBV and are more prone to HBV infection through vari-
ous other ways.

![Figure 1](image-url) The Prevalence of HBV Markers Related to Age Groups

In concordance with other published reports, our findings showed that HBV infection is more common in males than females (12, 18, 23). Although in the forward regression analysis of our study, there was an association between HBsAg and gender, while the backward regression analysis did not show the same result. Alavian et al. revealed a higher prevalence of HBV among men than women in Iran (2.55% vs. 2.03% respectively) (12). Some research groups did not find a difference between genders (9, 18, 23, 25). This difference could be related to higher exposure of males to hepatitis B risk factors.

In a study on 1264 HBV positive subjects, it was concluded that family history of hepatitis, history of dental surgery, history of transfusion and marriage were risk factors of infection. Therefore, marriage status can be considered as an interfamilial transmission in adults who have not received vaccination (23, 26).

There are a limited number of studies comparing the prevalence of HBV infection in rural and urban areas in Iran. In our study, the prevalence of HBsAg in rural areas was twice as high as urban areas (1.36% vs. 0.63%). This result is comparable with the findings of other investigators in different provinces of Iran (25). However, the rates of HBeAb in urban and rural areas in the current study were quite similar (10.51% and 10.64%, respectively). In conclusion, the prevalence of HBV infection in the north central province, northern Iran was almost lower than other reports from Iran country. Moreover, continuing public education about hepatitis B as well as adequate vaccination and screening programs among high-risk groups should be considered to control the infection.

Acknowledgements

The authors would like to thank Farzaneh Zamani, Mah- mood ghasemi, Dr. Shakira Ghafor and all staffs in GIL-DRC, Amol center. The ethical committee of Gastrointestinal and Liver Disease Research Center (GILDRC) Tehran approved this project.

Authors’ Contributions

Masoudreza Sohrabi and Hossein Keyvani contributed equally as first author in this study. Masoudreza Sohrabi: Data acquisition, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, intellectual contribution. Hossein Keyvani: Intellectual contribution. Hossein Poustchi: Intellectual contribution. Mahnood Reza Khoonsari: Intellectual contribution. Gholamreza Hemmasti: Intellectual contribution. Mitra Ameli: Intellectual contribution. Masoumeh Moaadi: Data acquisition. Ashrafi: Intellectual contribution. Fatemeh Saeedian: Intellectual contribution. Farhad Zamani: Study concept and design, drafting of the manuscript, critical revision of the manuscript for intellectual content and study supervision.

Funding/Support

This study was granted by the Digestive Research Centre affiliated to Iran University of Medical Sciences.

References

1. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol. 2010;25(1):19–25.
2. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17(2):87–95.
3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.
4. Riaz M, Idrees M, Kanwal H, Kabir F. An overview of triple infection with hepatitis B, C and D viruses. Virol J. 2011;8:368.
5. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005;34 Suppl 1:S1–3.
6. Specialist Panel on Chronic Hepatitis B at ME. A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. J Viral Hepat. 2012;19(1):9–22.
7. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine. 2000;18 Suppl 1:S20–2.
8. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2005;11(1):62–7.
9. Alavian SM, Tabatabaei SV, Ghashimi T, Beerdapur F, Kafi-Abad SA, Gharehbhagian A, et al. Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study. Int J Prev Med. 2012;3(1):770–5.
10. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev. 2010;11(4):859–62.
11. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403–6.
12. Alavian SM, Hajiri-zadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008;8(4).
13. Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. *Transfusion*. 2009;49(10):2214–20.

14. Alavian SM, Fallahian F, Lankarani KB. Implementing strategies for hepatitis B vaccination. *Saudi J Kidney Dis Transpl*. 2009;20(1):10–22.

15. Ramezani A, Amirmoezi R, Volk JE, Aghakhani A, Zarinfar N, McFarland W, et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. *AIDS Care*. 2004;16(9):2122–6.

16. Attaran MS, Sharifi Z, Hosseini SM, Samei S, Ateez Z. Prevalence of hepatitis B and hepatitis D coinfection in asymptomatic blood donors in Iran. *APMIS*. 2014;122(3):243–7.

17. Shakeri MT, Faghanian B, Nomani H, Ghayour-Mobarhan M, Nabavinia MS, Rostami S, et al. The prevalence of hepatitis B virus infection in mashhad, Iran: a population-based study. *Arch Iran Med*. 2013;16(3):245–8.

18. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. *Iran Red Crescent Med J*. 2013;15(3):225–31.

19. Moghaddam ES, Khosravi S, Ghorbani GA, Alavian SM. Hepatitis B core antibody in blood donor in Sistan-Balutuestan province of Iran. *Indian J Med Sci*. 2010;64(9):391–5.

20. Ramezani A, Banifazl M, Eslamifar A, Aghakhani A. Serological pattern of anti-HBc alone infers occult hepatitis B virus infection in high-risk individuals in Iran. *J Infect Dev Ctries*. 2010;4(10):658–61.

21. Salehi M, Alavian SM, Tabatabaei SV, Izadi S, Sanei Moghaddam E, Amini Kafi-Abad S, et al. Seroepidemiology of HBV infection in South-East of Iran; a population based study. *Iran Red Crescent Med J*. 2012;14(5):283–8.

22. Behzad-Belbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB, Torab A, Moaddeb A. Anti-HBC & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. *Indian J Med Res*. 2006;123(1):37–42.

23. Fathimoghaddam F, Hedayat-Moghaddam MR, Bidkhor HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran. *Hepat Mon*. 2011;11(5):346–50.

24. Ghadir MR, Belbasi M, Heidari A, Jandagh M, Ahmadi I, Habibinejad H, et al. Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. *Hepat Mon*. 2012;12(2):112–7.

25. Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in Zahedan city, Iran: a population-based study. *Hepat Mon*. 2012;12(9).

26. Hajian E, Hashemi SJ, Masjedizadeh AR. Seroepidemiology of Hepatitis B virus infection in Khuzestan province, southwest of Iran. *Hepat Mon*. 2009;9(1):34–8.